阜阳哪家皮肤医院有名阜阳治疗足癣医院,阜阳治疗皮肤病医院好,阜阳痤疮大约要花多少钱,阜阳医院股癣哪家好,荨麻疹医院阜阳哪个好,阜阳治疗皮肤过敏去哪里,阜阳治扁皮疣去哪家医院好

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

BEIJING, Sept. 6 (Xinhuanet) -- A short-term memory loss may suggest the Alzheimer's disease, according to a new study made by Spanish researchers.The finding was published on Monday, in Archives of General Psychiatry, an American Medical Association journal.The researchers gathered data of 116 people with mild cognitive impairment (MCI) who developed Alzheimer's disease within two years, 204 patients with the condition who didn't develop Alzheimer's and 197 people with no cognitive problems.Mild cognitive impairment is usually marked by difficulties with short-term memory, such as losing your train of thought repeatedly or having trouble remembering what you did yesterday, according to the study.After assessing them by biomarker tests and cognitive measures, the researcher found the cognitive markers can forecast the variance."Remarkably, they accounted for nearly 50% of the predictive variance," said Dr. Gomar of Centro de Investigation Biomedica en Red de Salud Mental, Barcelona, who led the research.Mild cognitive impairment at the start of the study was a stronger predictor of Alzheimer's than most biomarkers, the researchers concluded.

BEIJING, August 1 (Xinhuanet) -- U.S. researchers have discovered a genetic mutation unique to African Americans that links to heighten their asthma risk, according to reports published on Sunday in the journal Nature Genetics.Researchers of University of Chicago found a gene, PYHIN1, and its variations may account for asthma risk in people of African descent. In their study, they examined data from nine previous genome-wide association studies, totaling more than 2 million single nucleotide polymorphisms in 3,246 asthma patients and 3,385 control patient, 1,702 patient-parent groupings, 355 family-based cases, and 468 family-based controls.In the study, the researchers found that between 26 percent and 29 percent of people of African-descent carried at least one copy of the gene.  In particular, one polymorphism of the gene was 34 percent more likely found in African-American and Afro-Caribbean people with asthma.  More interestingly, this variant of the gene is rarely found in Caucasian people and in Latino population, it was found in less than 5 percent.This new variant is part of a family of genes linked with the body's response to viral infections. It is thought to be involved in interferon signaling, which could influence the occurrence of asthma.The team stressed that each gene variant on its own plays only a small role in increasing asthma risk, but that risk could be multiplied when combined with other risk genes and with environmental factors.

STOCKHOLM, July 7 (Xinhua) -- A patient has been given a new trachea made from a synthetic scaffold seeded with his own stem cells in a Stockholm's hospital, the Swedish medical university Karolinska Institutet said on Thursday.The operation was performed on June 9th at Karolinska University Hospital in Huddinge and the patient, a 36-year old man, has been well on the way to recovery and would be discharged from the hospital on Friday, the university said in a statement.The patient had been suffering from late stage tracheal cancer with the tumor had reached approximately 6cm in length and was extending to the main bronchus.Since no suitable donor windpipe was available, the transplantation of the synthetic tissue engineered trachea was performed as the last possible option for the patient.The successful transplantation of tissue engineered synthetic organs, referred to as regenerative medicine, could open promising therapeutic possibilities for the thousands of patients who suffer from similar conditions.Transplantations of tissue engineered windpipes with synthetic scaffolds in combination with the patient's own stem cells as a standard procedure means that patients would not have to wait for a suitable donor organ.This would be a substantial benefit for patients since they could benefit from earlier surgery and have a greater chance of cure, according to the statement.